Skip to main content
logo
China SXT Pharmaceuticals, Inc. (SXTC)
NASDAQ: SXTC · Real-Time Price · USD
2.360
-0.300 (-11.28%)
At close: Sep 15, 2026, 4:00 PM EDT
2.370
+0.010 (0.42%)
After-hours: Sep 15, 2026, 4:13 PM EDT

China SXT Pharmaceuticals Income Statement

Millions USD. Fiscal year is Apr - Mar.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
1.141.741.931.972.6
Revenue Growth
-34.63%-9.73%-2.19%-24.23%-45.53%
Cost of Revenue
0.891.371.371.551.35
Gross Profit
0.250.370.550.431.25
Selling, General & Admin
7.373.052.655.686.44
Operating Expenses
7.373.052.655.686.44
Operating Income
-7.12-2.68-2.09-5.26-5.19
Interest Expense
-0.06-0.65-0.55-0.48-0.04
Interest & Investment Income
-00.01-0
Other Non Operating Income (Expenses)
0.980.03-0.040.15-0.18
EBT Excluding Unusual Items
-6.21-3.3-2.68-5.59-5.41
Asset Writedown
---0.42-0.35-
Pretax Income
-6.21-3.3-3.1-5.93-5.41
Income Tax Expense
----0.33
Net Income
-6.21-3.3-3.1-5.93-5.74
Net Income to Common
-6.21-3.3-3.1-5.93-5.74
Net Income Growth
-----
Shares Outstanding (Basic)
----2
Shares Outstanding (Diluted)
----2
Shares Change
-----86.91%
EPS (Basic)
-----2.82
EPS (Diluted)
-----2.82
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
-4.02-2.35-1.94-0.150.21
Free Cash Flow Per Share
----0.10
Gross Margin
21.85%21.11%28.73%21.62%48.10%
Operating Margin
-625.89%-153.97%-108.49%-266.68%-199.43%
Profit Margin
-545.24%-189.77%-160.67%-301.00%-220.43%
Free Cash Flow Margin
-353.01%-134.83%-100.34%-7.68%7.91%
EBITDA
-7.05-2.6-1.89-5.01-4.87
EBITDA Margin
--149.24%-97.95%-253.99%-187.13%
D&A For EBITDA
0.070.080.20.250.32
EBIT
-7.12-2.68-2.09-5.26-5.19
EBIT Margin
--153.97%-108.49%-266.68%-199.43%
Revenue as Reported
1.141.741.931.972.6
SEC Filings: 10-K · 10-Q